Dusa Pharma (Dusa)

[surf1944]

6:33AM DUSA Pharma announces independent study utilizing cyclic levulan PDT finds 95% reduction in new squamous cell carcinoma lesions in solid organ transplant recipients over a 2 yr period (DUSA) 1.41 : Co announces the results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas in solid organ transplant recipients, a population with a high incidence of nonmelanoma skin cancer. This pilot study, which will also appear in the print version of the December issue of Dermatologic Surgery, was conducted by researchers at the University of Minnesota Department of Dermatology and found that the median number of SCCs was reduced by 79% at 12 months after cyclic Levulan PDT treatment and by 95% at 24 months, when compared to the pre-PDT year measurement date. "These results are another step forward in managing and improving the health of SOTR patients who have a much higher risk than the general population of developing SCCs, a skin cancer that is often times deadly in this patient population..."